LifeArc, the UK-based self-funded medical research organization, has entered a partnership with Elpida Therapeutics to advance three AAV gene therapy programs targeting ultra-rare neurodegenerative conditions in children, with LifeArc contributing clinical, translational, and regulatory expertise alongside financial support. The programs cover spastic paraplegia type 50 (SPG50), neuronal ceroid lipofuscinosis 7 (CLN7 Batten disease), and Charcot–Marie–Tooth disease type 4J (CMT4J) — none of which has an approved treatment. Elpida's lead asset, Melpida, an AAV9-based gene therapy for SPG50, entered a pivotal Phase III trial in the US in April 2026, making the collaboration notable for its inclusion of a program already at a registrational stage.
Financial terms were not disclosed.
Melpida is described by Elpida as an AAV9 vector delivering a functional copy of the AP4M1 gene, designed to address the root genetic cause of SPG50. The disease results from loss-of-function mutations in AP4M1, which encodes a subunit of the AP-4 adaptor protein complex responsible for axonal cargo sorting and transport in neuronal cells. Disruption of this pathway causes progressive spasticity, intellectual disability, and developmental regression in affected children. Trial registry records link the asset to two registered studies — NCT06069687 and NCT06692712 — with the latter's scientific title referencing Melpida as "AAV9/AP4M1."
Elpida was founded in 2023 by Terry and Georgia Pirovolakis after their son Michael was diagnosed with SPG50. The organization's name derives from the Greek word for hope, and Melpida translates as "Michael's Hope." The company has completed early-stage clinical evaluation of Melpida in the US and Europe and enrolled the first patients in its US pivotal study in April 2026, with an stated ambition of achieving US FDA approval by early 2028.